4.7 Review

Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases

Journal

ACTA PHARMACEUTICA SINICA B
Volume 12, Issue 4, Pages 1740-1760

Publisher

INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2022.01.007

Keywords

CTGF; CCN2; CCN family; Fibrosis; Cancer; Targeted therapy; Immunotherapy; Therapeutic strategies

Funding

  1. National Science Foundation for Excellent Young Scholars [32122052]
  2. National Natural Science Foundation Regional Innovation and Development [U19A2003]

Ask authors/readers for more resources

Connective tissue growth factor (CTGF) is a multifunctional protein that regulates various cellular processes and is involved in disease-related pathways. It may serve as a potential therapeutic target for the treatment of different diseases. Recent research has shown promising outcomes in clinical and preclinical trials of drugs targeting CTGF.
Connective tissue growth factor (CTGF), a multifunctional protein of the CCN family, regulates cell proliferation, differentiation, adhesion, and a variety of other biological processes. It is involved in the disease-related pathways such as the Hippo pathway, p53 and nuclear factor kappa-B (NF-kappa B) pathways and thus contributes to the developments of inflammation, fibrosis, cancer and other diseases as a downstream effector. Therefore, CTGF might be a potential therapeutic target for treating various diseases. In recent years, the research on the potential of CTGF in the treatment of diseases has also been paid more attention. Several drugs targeting CTGF (monoclonal antibodies FG3149 and FG3019) are being assessed by clinical or preclinical trials and have shown promising outcomes. In this review, the cellular events regulated by CTGF, and the relationships between CTGF and pathogenesis of diseases are systematically summarized. In addition, we highlight the current researches, focusing on the preclinical and clinical trials concerned with CTGF as the therapeutic target. (C) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available